It is the first and only treatment that has been approved for geographic atrophy, a leading cause of blindness, according to a Feb. 17 news release.
Syfovre is set to be available to specialty distributors and pharmacies across the country in March.
FDA approves first and only treatment for leading cause of blindness
Apellis Pharmaceuticals’ Syfovre, a treatment for geographic atrophy, has received FDA approval.
Shared risk, shared data: What leaders say is really driving payer-provider alignment
Recommended Whitepaper